Current perspectives in therapeutic myocardial angiogenesis

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Biotechnology

Background:

• Vascular endothelial growth factor (VEGF) and other angiogenic factors are key to blood vessel formation.
• Obstructive arterial disease causes myocardial and leg ischemia, leading to significant morbidity.
• Therapeutic angiogenesis offers a novel treatment strategy for ischemic conditions.

Purpose of the Study:

• To review the current evidence on the safety, feasibility, and efficacy of angiogenic techniques.
• To summarize diverse methodologies employed in clinical trials for therapeutic angiogenesis.
• To highlight emerging cell-based therapies for enhancing myocardial blood flow.

Main Methods:

• Review of published clinical trials (over 900 patients) investigating myocardial angiogenesis.
• Analysis of different angiogenic agents, including proteins, master genes, and cell therapies.
• Examination of various delivery routes: intracoronary, intramyocardial, transepicardial, and transendocardial.

Main Results:

• At least 17 clinical trials for myocardial angiogenesis have been conducted.
• Intracoronary delivery of angiogenic proteins is the most common method.
• Emerging research focuses on cell therapy, with Phase I/II trials initiating.

Conclusions:

• Optimal delivery route and angiogenic agent for therapeutic angiogenesis remain under investigation.
• Cell therapy shows promise as a novel approach for angiogenesis.
• Further research is needed to establish the definitive safety and efficacy of these techniques.